Lung Cancer Advisory Board

https://www.cancercommons.org/wordpress/wp-content/uploads/2017/01/ravi_salgia.jpg

Ravi Salgia, M.D., Ph.D.

Lead

Dr. Salgia is the Arthur & Rosalie Kaplan Chair and Professor in Medical Oncology and the associate director for clinical sciences research in City of Hope’s Comprehensive Cancer Center. He is the Professor in Division of Mathematical Oncology and Executive Medical Director, Biomedical Data Science, Center for Informatics at City of Hope, as well as Adjunct Professor for the Integrated Cancer Genomics Division at the Translational Genomics Research Institute. Prior to joining City of Hope, Dr. Salgia served in a variety of leadership roles at the Comprehensive Cancer Center of the University of Chicago, where he is now Professor Emeritus. He was a faculty member for ten years at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Salgia earned his undergraduate degrees, medical doctorate, and Ph.D. from Loyola University in Chicago, IL. He continued his training at The Johns Hopkins Hospital in Baltimore, MD, followed by fellowships at Dana-Farber Cancer Institute and Harvard Medical School.

Board-certified in both internal medicine and medical oncology, Dr. Salgia serves on various panels for the National Cancer Institute. He has consistently received research grants from the NIH for his research work and has been awarded several invention discoveries and patents related to his work. He is the co-chief editor for the Journal of Carcinogenesis. He has authored nearly 350 peer-reviewed articles, reviews and editorials, one book, and 34 book chapters. He has an h-index of 77 and over 16,000 citations. Dr. Salgia is frequently invited to present his work at national and international conferences and symposia and is the recipient of several honors and awards. He recently joined the board of directors at the NCCN.

 

Hatim Husain, M.D.

Dr. Husain is a lung cancer medical oncologist pursuing a translational career in cancer therapeutic strategies in solid tumor malignancies. His passion is to be involved in early drug development, and his goal is to develop a translational laboratory for biomarker validation and drug testing in in vitro and in vivo models that can form the basis for early phase clinical trials. He works very closely to characterize technology development in the circulating tumor DNA space and applications about its utility. He has also recently been involved in understanding mechanisms of resistance to anti-EGFR directed therapies and further understanding the mechanisms of immunogenic cell death in cancer cells.

 

Christine M. Lovly, M.D., Ph.D.

Dr. Lovly is currently an Assistant Professor of Medicine and Cancer Biology at the Vanderbilt University School of Medicine and Vanderbilt Ingram Cancer Center. She received a B.A. in chemistry from Johns Hopkins University followed by M.D. and Ph.D. degrees as part of the Medical Scientist Training Program at Washington University in St. Louis, MO. She then completed internal medicine residency and medical oncology subspecialty training at Vanderbilt University. During her final year of fellowship, she was the Jim and Carol O’Hare Chief Fellow. She started on faculty at Vanderbilt as Assistant Professor in July 2013. Her laboratory research is directed at understanding and developing improved therapeutic strategies for specific clinically relevant molecular subsets of cancer.

Dr. Lovly has received grant funding from Uniting Against Lung Cancer, the Conquer Cancer Foundation of the American Society of Clinical Oncology, the Sarcoma Foundation of America, the American Cancer Society, the Damon Runyon foundation, the LUNGevity foundation, the V Foundation, the American Association for Cancer Research, and Lung Cancer Foundation of America / International Association for the Study of Lung Cancer. She is the author of several peer-reviewed scientific manuscripts, and she is an active member in the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC), and the American Association for Cancer Research (AACR). She is co-Editor-In-Chief for the website www.mycancergenome.org, a Vanderbilt initiated, freely available website which aims to provide health care practitioners, patient, and advocates with up-to-date information regarding genetically informed cancer medicine. Dr. Lovly is also an elected member of the American Society for Clinical Investigation (ASCI).

 

https://www.cancercommons.org/wordpress/wp-content/uploads/2017/01/gregory_otterson1.jpg

Gregory Otterson, M.D.

Dr. Otterson is Professor in the College of Medicine at Ohio State University (OSU) Comprehensive Cancer Center James Cancer Hospital. Dr. Otterson is broadly interested in improving the care and understanding of thoracic malignancies (adenocarcinoma, squamous carcinoma, large cell carcinoma, never-smoking adenocarcinoma, small cell lung cancer, mesothelioma, and thymic cancers). His research centers around the genetic and epigenetic changes in lung cancers, particularly microRNAs. Therapeutically, he is interested in understanding how better to target specific therapies to specific patients, that is, understanding which patients will respond to which therapeutic maneuvers. Dr. Otterson has active collaborations within OSU, including in the Division of Cancer Genetics (Carlo Croce), the School of Public Health (Mary Ellen Wewers and Amy Ferketich), and the Division of Pulmonary and Critical Care Medicine (Patrick Nana-Sinkam). Outside of OSU, he works with investigators at the University of Minnesota and also actively works with the Cancer and Leukemia Group B, having been National Principal Investigator on three studies through the Respiratory Committee.

 

https://www.cancercommons.org/wordpress/wp-content/uploads/2017/01/george_simon.jpg

George Simon, M.D.

Dr. Simon is currently Associate Professor of Medicine and Oncology at the Medical University of South Carolina, Charleston. He also serves as Assistant Director of Clinical Investigation at the Hollings Cancer Center and is the Burtschy Family Distinguished Endowed Chair in Cancer Research. Previously, he served as the director of the Thoracic Oncology Program, Department of Medical Oncology at Fox Chase Cancer Center in Philadelphia, Pennsylvania. After earning his medical degree from the Christian Medical College and Hospital, Ludhiana in Punjab, India, Dr. Simon completed residencies in internal medicine at the Christina Medical College and Hospital, Punjab, India and St. Joseph’s Hospital, Denver, Colorado, and a fellowship in medical oncology and hematology at the University of Colorado Health Sciences Center in Denver. Previously, Dr. Simon has served as the director of a mesothelioma research program at the H. Lee Moffitt Cancer Center, Tampa, Florida. Prior to joining the H. Lee Moffitt Cancer Center, Dr. Simon served as Director of Clinical Investigation in the Division of Hemotology and Oncology at the Denver Health Medical Center. Dr. Simon has served as a member of the National Comprehensive Cancer Network (NCCN) Non-Small Cell Lung Cancer Guidelines panel, American College of Chest Physician Lung Cancer Guidelines committee, and in the Thoracic Core committee of the South West Oncology Group. He currently serves in the Thoracic Core committee of the Eastern Cooperative Oncology Group. Dr. Simon is an ad hoc reviewer for several panels of the National Institutes of Health, National Cancer Institute, and Department of Defense, and also a reviewer for several journals including Cancer Research, Clinical Cancer Research, Chest, Cancer, Journal of Clinical Oncology, Journal of Thoracic Oncology, and Indian Journal of Cancer. He is author or coauthor of more than 70 peer-reviewed research publications, 13 book chapters, and more than 65 abstracts.

 

David Spigel, M.D.

Dr. Spigel serves as Chief Scientific Officer, Director of the Lung Cancer Research Program, and Principal Investigator at Sarah Cannon Research Institute. He joined Sarah Cannon in 2003 and as chief scientific officer, he oversees all scientific aspects of Sarah Cannon’s clinical trial program, working with the research physician leaders to ensure the best new agents and studies are available to our patients. He serves as a primary contact for the pharma and biotech partners as well as the strategic site physicians with whom Sarah Cannon conducts cancer research.

Spigel received his bachelor’s degree from Tulane University in New Orleans in 1992, and medical degree from The University of Tennessee in Memphis in 1996. After completing an internal medicine and chief residency at Indiana University Medical Center, he completed a fellowship in hematology and oncology at The Dana-Farber Cancer Institute in Boston. He is board certified in medical oncology. Additionally, he is an associate with Tennessee Oncology, PLLC.

Emeritus Lung Cancer Advisory Board

Phillip Dennis, M.D., Ph.D.
Nicholas Campbell, M.D.
Raphael Bueno, M.D.